Physician profile
Michael Hollins
NPI 1922589894
$1,595.42
in general payments reported to CMS, 2019-2025
12 companies · $79.81 in 2025
The $79.81 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.23 · 2021: $148 · 2022: $764 · 2023: $357 · 2024: $200 · 2025: $79.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $518.80 | 2022 | |
| Bausch & Lomb Americas INC. | $202.23 | 2022-2024 | Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $184.81 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $176.27 | 2021-2024 | Cequa |
| Oyster Point Pharma, INC. | $170.20 | 2022-2023 | Tyrvaya |
| Horizon Therapeutics Plc | $79.73 | 2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $65.39 | 2023-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $56.24 | 2023-2024 | Purified Cortrophin Gel |
| Alcon Vision LLC | $52.20 | 2020-2023 | Total30 |
| Novartis Pharmaceuticals Corporation | $41.37 | 2020-2021 | |
| Coopervision INC. | $33.71 | 2022-2024 | Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.